Advanced search in
Research products
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
Include:
The following results are related to Canada. Are you interested to view more results? Visit OpenAIRE - Explore.
8,859 Research products, page 1 of 886

  • Canada
  • Publications
  • Research software
  • CZ

10
arrow_drop_down
Relevance
arrow_drop_down
  • Open Access
    Authors: 
    Societies Editorial Office;
    Publisher: MDPI AG

    The editors of Societies would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2013. [...]

  • Open Access
    Authors: 
    Andrew Spencer; Suzanne Lentzsch; Katja Weisel; Hervé Avet-Loiseau; Tomer M Mark; Ivan Spicka; Tamás Masszi; Birgitta Lauri; Mark-David Levin; Alberto Bosi; +27 more
    Publisher: Ferrata Storti Foundation (Haematologica)
    Countries: Netherlands, Italy

    Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0–27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P12, ≤6, or >6 months), or cytogenetic risk. Minimal residual disease–negative rates were >2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. Trial registration: clinicaltrials.gov identifier: 02136134.

  • Publication . Article . 2017
    Open Access
    Authors: 
    Alena Skálová; Michal Michal; Roderick H.W. Simpson;
    Publisher: Springer Science and Business Media LLC

    This review concentrates on three salivary gland tumors that have been accepted in the recent literature as new neoplastic entities: mammary analog secretory carcinoma (MASC), sclerosing polycystic adenoma (SPA) and cribriform adenocarcinoma of tongue and other minor salivary glands (CAMSGs). MASC is a distinctive low-grade malignant salivary cancer that harbors a characteristic chromosomal translocation, t(12;15) (p13;q25) resulting in an ETV6–NTRK3 fusion. SPA is a rare lesion often mistaken histologically for low-grade salivary carcinoma. Previously thought to be a reactive fibroinflammatory process, but recent evidence of clonality, recurrences in up 30%, and dysplastic foci suggest it may be truly neoplastic. CAMSG is a distinct tumor entity that differs from polymorphous low-grade adenocarcinoma (PLGA) by location (ie, most often arising on the tongue), by prominent nuclear clearing, alterations of the PRKD gene family and clinical behavior with frequent metastases at the time of presentation of the primary tumor. Early metastatic disease seen in most cases of CAMSG associated with indolent behavior makes it a unique neoplasm among all low-grade salivary gland tumors. Salivary glands may give rise to a wide spectrum of different tumors. They are often diagnostically challenging as morphological features often overlap between different entities. Although conventional morphology in combination with immunohistochemical findings still provide the most important clues for diagnosis, recent advances in molecular pathology offer new diagnostic tools in investigating the differential diagnosis, as well as providing potentially valuable prognostic indicators. In the last two decades, several new salivary gland tumor entities have been described, namely MASC, SPA and CAMSGs.

  • Open Access
    Authors: 
    Morad Aaboud; Alexander Kupco; Stefan Schmitt; Ahmed Bassalat; Matej Melo; Marjorie Shapiro; Grigore Tarna; Till Eifert; Maximiliano Sioli; Nello Bruscino; +816 more
    Publisher: American Physical Society (APS)
    Project: NSERC

    A measurement of the associated production of a top-quark pair (tt) with a vector boson (W, Z) in proton-proton collisions at a center-of-mass energy of 13 TeV is presented, using 36.1 fb-1 of integrated luminosity collected by the ATLAS detector at the Large Hadron Collider. Events are selected in channels with two same- or opposite-sign leptons (electrons or muons), three leptons or four leptons, and each channel is further divided into multiple regions to maximize the sensitivity of the measurement. The ttZ and ttW production cross sections are simultaneously measured using a combined fit to all regions. The best-fit values of the production cross sections are σttZ=0.95±0.08stat±0.10syst pb and σttW=0.87±0.13stat±0.14syst pb in agreement with the Standard Model predictions. The measurement of the ttZ cross section is used to set constraints on effective field theory operators which modify the ttZ vertex.

  • Publication . Article . 2015
    Open Access
    Authors: 
    Jiří Vohánka; Mir Faizal;
    Publisher: American Physical Society (APS)

    In this paper, we will analyze three-dimensional supersymmetric Yang-Mills theory coupled to matter fields in $SIM(1)$ superspace formalism. The original theory which is invariant under the full Lorentz group has $\mathcal{N}=1$ supersymmetry. However, when we break the Lorentz symmetry down to $SIM(1)$ group, the $SIM(1)$ superspace will break half the supersymmetry of the original theory. Thus, the resultant theory in $SIM(1)$ superspace will have $\mathcal{N}=1/2$ supersymmetry. This is the first time that $\mathcal{N}=1$ supersymmetry will be broken down to $\mathcal{N}=1/2$ supersymmetry, for a three-dimensional theory, on a manifold without a boundary. This is because it is not possible to use nonanticommutativity to break $\mathcal{N}=1$ supersymmetry down to $\mathcal{N}=1/2$ supersymmetry in three dimensions.

  • Open Access
    Authors: 
    Schellenberg, D; Armstrong Schellenberg, J R M; Mushi, A; Savigny de, D; Mgalula, L; Mbuya, C; Victoria, C.G.;
    Country: Tanzania (United Republic of)

    Objective was to document the prevalence, age-distribution, and risk factors for anaemia in Tanzanian children less than 5 years old,thereby assisting in the development of effective strategies for controlling anaemia. Cluster sampling was used to identify 2417 households at random from four contiguous districts in south-eastern United Republic of Tanzania in mid-1999. Data on various social and medical parameters were collected and analysed. Blood haemoglobin concentrations (Hb) were available for 1979 of the 2131 (93%) children identified and ranged from 1.7 to 18.6 g/dl. Overall, 87% (1722) of children had an Hb <11 g/dl, 39% (775) had an Hb <8 g/dl and 3% (65) had an Hb <5 g/dl. The highest prevalence of anaemia of all three levels was in children aged 6–11 months, of whom 10% (22/226) had an Hb <5 g/dl. However, the prevalence of anaemia was already high in children aged 1–5 months (85% had an Hb <11 g/dl, 42% had an Hb <8 g/dl, and 6% had an Hb <5 g/dl). Anaemia was usually asymptomatic and when symptoms arose they were nonspecific and rarely identified as a serious illness by the care provider. A recent history of treatment with antimalarials and iron was rare. Compliance with vaccinations delivered through the Expanded Programme of Immunization (EPI) was 82% and was notassociated with risk of anaemia. Anaemia is extremely common in south-eastern United Republic of Tanzania, even in very young infants. Further implementation of the Integrated Management of Childhood Illness algorithm should improve the case management of anaemia. However, the asymptomatic nature of most episodes of anaemia highlights the need for preventive strategies. The EPI has good coverage of the target population and it may be an appropriate channel for delivering tools for controlling anaemia and malaria.

  • Open Access
    Authors: 
    Zdenka Ellederova; Sonia del Rincon; Marketa Koncicka; Andrej Susor; Michal Kubelka; Dahui Sun; Charles Spruck;
    Publisher: American Society for Microbiology

    Cell division cycle (Cdc) kinase subunit (CKS) proteins bind cyclin-dependent kinases (CDKs) and play important roles in cell division control and development, though their precise molecular functions are not fully understood. Mammals express two closely related paralogs called CKS1 and CKS2, but only CKS2 is expressed in the germ line, indicating that it is solely responsible for regulating CDK functions in meiosis. Using cks2(−/−) knockout mice, we show that CKS2 is a crucial regulator of maturation-promoting factor (MPF; CDK1-cyclin A/B) activity in meiosis. cks2(−/−) oocytes display reduced and delayed MPF activity during meiotic progression, leading to defects in germinal vesicle breakdown (GVBD), anaphase-promoting complex/cyclosome (APC/C) activation, and meiotic spindle assembly. cks2(−/−) germ cells express significantly reduced levels of the MPF components CDK1 and cyclins A1/B1. Additionally, injection of MPF plus CKS2, but not MPF alone, restored normal GVBD in cks2(−/−) oocytes, demonstrating that GVBD is driven by a CKS2-dependent function of MPF. Moreover, we generated cks2(cks1/cks1) knock-in mice and found that CKS1 can compensate for CKS2 in meiosis in vivo, but homozygous embryos arrested development at the 2- to 5-cell stage. Collectively, our results show that CKS2 is a crucial regulator of MPF functions in meiosis and that its paralog, CKS1, must be excluded from the germ line for proper embryonic development.

  • Publication . Article
    Open Access English
    Publisher: Published by Elsevier Inc.
  • Open Access English
    Authors: 
    Mares, J.; Friedman, E.; Gal, A.; Jennings, B. K.;
    Project: NSERC

    Strong interaction level shifts and widths in $\Sigma^-$ atoms are analyzed by using a $\Sigma$ nucleus optical potential constructed within the relativistic mean field approach. The analysis leads to potentials with a repulsive real part in the nuclear interior. The data are sufficient to establish the size of the isovector meson--hyperon coupling. Implications to $\Sigma$ hypernuclei are discussed. Comment: 18 pages, RevTex, 4 uuencoded figures, subm. Nucl.Phys.A

  • Open Access
    Authors: 
    Graham J. Schapel; Sheila J. Wallace; Gillian S. Gordon;
    Publisher: Elsevier BV

    A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994, identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales. Of 79 patient treatments with LTG and 86 with GVG, 42 patients were treated with add-on LTG, 52 with add-on GVG and 20 with both drugs simultaneously. A Kaplan-Meier curve, applied to each of the two index drugs, indicated that 71 and 62% of patients would be expected to continue taking LTG or GVG, respectively after 40 months. Improved seizure control (≥ 50%) at the time of audit was seen in 65% of LTG and 58% of GVG patient treatments for all epilepsy syndromes, but there was a higher proportion of patients with generalized epilepsy improved by LTG (28/41, 68%) than that improved by GVG (8/20, 40%), and only those with generalized epilepsy treated with LTG became seizure free (8/38, 21%). Similar proportions of patients discontinued LTG (16%) and GVG (15%) due to an adverse experience, but a higher proportion discontinued GVG (18%) compared with LTG (6%) because of lack of efficacy. This study supports the relative clinical effectiveness of LTG and GVG in the real world, where children with severe epilepsy are treated in clinical practice and serves to generate hypotheses to enable design of prospectively controlled trials, which should enable more rational use of these two drugs in the paediatric population with epilepsy.

Advanced search in
Research products
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
Include:
The following results are related to Canada. Are you interested to view more results? Visit OpenAIRE - Explore.
8,859 Research products, page 1 of 886
  • Open Access
    Authors: 
    Societies Editorial Office;
    Publisher: MDPI AG

    The editors of Societies would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2013. [...]

  • Open Access
    Authors: 
    Andrew Spencer; Suzanne Lentzsch; Katja Weisel; Hervé Avet-Loiseau; Tomer M Mark; Ivan Spicka; Tamás Masszi; Birgitta Lauri; Mark-David Levin; Alberto Bosi; +27 more
    Publisher: Ferrata Storti Foundation (Haematologica)
    Countries: Netherlands, Italy

    Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0–27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P12, ≤6, or >6 months), or cytogenetic risk. Minimal residual disease–negative rates were >2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. Trial registration: clinicaltrials.gov identifier: 02136134.

  • Publication . Article . 2017
    Open Access
    Authors: 
    Alena Skálová; Michal Michal; Roderick H.W. Simpson;
    Publisher: Springer Science and Business Media LLC

    This review concentrates on three salivary gland tumors that have been accepted in the recent literature as new neoplastic entities: mammary analog secretory carcinoma (MASC), sclerosing polycystic adenoma (SPA) and cribriform adenocarcinoma of tongue and other minor salivary glands (CAMSGs). MASC is a distinctive low-grade malignant salivary cancer that harbors a characteristic chromosomal translocation, t(12;15) (p13;q25) resulting in an ETV6–NTRK3 fusion. SPA is a rare lesion often mistaken histologically for low-grade salivary carcinoma. Previously thought to be a reactive fibroinflammatory process, but recent evidence of clonality, recurrences in up 30%, and dysplastic foci suggest it may be truly neoplastic. CAMSG is a distinct tumor entity that differs from polymorphous low-grade adenocarcinoma (PLGA) by location (ie, most often arising on the tongue), by prominent nuclear clearing, alterations of the PRKD gene family and clinical behavior with frequent metastases at the time of presentation of the primary tumor. Early metastatic disease seen in most cases of CAMSG associated with indolent behavior makes it a unique neoplasm among all low-grade salivary gland tumors. Salivary glands may give rise to a wide spectrum of different tumors. They are often diagnostically challenging as morphological features often overlap between different entities. Although conventional morphology in combination with immunohistochemical findings still provide the most important clues for diagnosis, recent advances in molecular pathology offer new diagnostic tools in investigating the differential diagnosis, as well as providing potentially valuable prognostic indicators. In the last two decades, several new salivary gland tumor entities have been described, namely MASC, SPA and CAMSGs.

  • Open Access
    Authors: 
    Morad Aaboud; Alexander Kupco; Stefan Schmitt; Ahmed Bassalat; Matej Melo; Marjorie Shapiro; Grigore Tarna; Till Eifert; Maximiliano Sioli; Nello Bruscino; +816 more
    Publisher: American Physical Society (APS)
    Project: NSERC

    A measurement of the associated production of a top-quark pair (tt) with a vector boson (W, Z) in proton-proton collisions at a center-of-mass energy of 13 TeV is presented, using 36.1 fb-1 of integrated luminosity collected by the ATLAS detector at the Large Hadron Collider. Events are selected in channels with two same- or opposite-sign leptons (electrons or muons), three leptons or four leptons, and each channel is further divided into multiple regions to maximize the sensitivity of the measurement. The ttZ and ttW production cross sections are simultaneously measured using a combined fit to all regions. The best-fit values of the production cross sections are σttZ=0.95±0.08stat±0.10syst pb and σttW=0.87±0.13stat±0.14syst pb in agreement with the Standard Model predictions. The measurement of the ttZ cross section is used to set constraints on effective field theory operators which modify the ttZ vertex.

  • Publication . Article . 2015
    Open Access
    Authors: 
    Jiří Vohánka; Mir Faizal;
    Publisher: American Physical Society (APS)

    In this paper, we will analyze three-dimensional supersymmetric Yang-Mills theory coupled to matter fields in $SIM(1)$ superspace formalism. The original theory which is invariant under the full Lorentz group has $\mathcal{N}=1$ supersymmetry. However, when we break the Lorentz symmetry down to $SIM(1)$ group, the $SIM(1)$ superspace will break half the supersymmetry of the original theory. Thus, the resultant theory in $SIM(1)$ superspace will have $\mathcal{N}=1/2$ supersymmetry. This is the first time that $\mathcal{N}=1$ supersymmetry will be broken down to $\mathcal{N}=1/2$ supersymmetry, for a three-dimensional theory, on a manifold without a boundary. This is because it is not possible to use nonanticommutativity to break $\mathcal{N}=1$ supersymmetry down to $\mathcal{N}=1/2$ supersymmetry in three dimensions.

  • Open Access
    Authors: 
    Schellenberg, D; Armstrong Schellenberg, J R M; Mushi, A; Savigny de, D; Mgalula, L; Mbuya, C; Victoria, C.G.;
    Country: Tanzania (United Republic of)

    Objective was to document the prevalence, age-distribution, and risk factors for anaemia in Tanzanian children less than 5 years old,thereby assisting in the development of effective strategies for controlling anaemia. Cluster sampling was used to identify 2417 households at random from four contiguous districts in south-eastern United Republic of Tanzania in mid-1999. Data on various social and medical parameters were collected and analysed. Blood haemoglobin concentrations (Hb) were available for 1979 of the 2131 (93%) children identified and ranged from 1.7 to 18.6 g/dl. Overall, 87% (1722) of children had an Hb <11 g/dl, 39% (775) had an Hb <8 g/dl and 3% (65) had an Hb <5 g/dl. The highest prevalence of anaemia of all three levels was in children aged 6–11 months, of whom 10% (22/226) had an Hb <5 g/dl. However, the prevalence of anaemia was already high in children aged 1–5 months (85% had an Hb <11 g/dl, 42% had an Hb <8 g/dl, and 6% had an Hb <5 g/dl). Anaemia was usually asymptomatic and when symptoms arose they were nonspecific and rarely identified as a serious illness by the care provider. A recent history of treatment with antimalarials and iron was rare. Compliance with vaccinations delivered through the Expanded Programme of Immunization (EPI) was 82% and was notassociated with risk of anaemia. Anaemia is extremely common in south-eastern United Republic of Tanzania, even in very young infants. Further implementation of the Integrated Management of Childhood Illness algorithm should improve the case management of anaemia. However, the asymptomatic nature of most episodes of anaemia highlights the need for preventive strategies. The EPI has good coverage of the target population and it may be an appropriate channel for delivering tools for controlling anaemia and malaria.

  • Open Access
    Authors: 
    Zdenka Ellederova; Sonia del Rincon; Marketa Koncicka; Andrej Susor; Michal Kubelka; Dahui Sun; Charles Spruck;
    Publisher: American Society for Microbiology

    Cell division cycle (Cdc) kinase subunit (CKS) proteins bind cyclin-dependent kinases (CDKs) and play important roles in cell division control and development, though their precise molecular functions are not fully understood. Mammals express two closely related paralogs called CKS1 and CKS2, but only CKS2 is expressed in the germ line, indicating that it is solely responsible for regulating CDK functions in meiosis. Using cks2(−/−) knockout mice, we show that CKS2 is a crucial regulator of maturation-promoting factor (MPF; CDK1-cyclin A/B) activity in meiosis. cks2(−/−) oocytes display reduced and delayed MPF activity during meiotic progression, leading to defects in germinal vesicle breakdown (GVBD), anaphase-promoting complex/cyclosome (APC/C) activation, and meiotic spindle assembly. cks2(−/−) germ cells express significantly reduced levels of the MPF components CDK1 and cyclins A1/B1. Additionally, injection of MPF plus CKS2, but not MPF alone, restored normal GVBD in cks2(−/−) oocytes, demonstrating that GVBD is driven by a CKS2-dependent function of MPF. Moreover, we generated cks2(cks1/cks1) knock-in mice and found that CKS1 can compensate for CKS2 in meiosis in vivo, but homozygous embryos arrested development at the 2- to 5-cell stage. Collectively, our results show that CKS2 is a crucial regulator of MPF functions in meiosis and that its paralog, CKS1, must be excluded from the germ line for proper embryonic development.

  • Publication . Article
    Open Access English
    Publisher: Published by Elsevier Inc.
  • Open Access English
    Authors: 
    Mares, J.; Friedman, E.; Gal, A.; Jennings, B. K.;
    Project: NSERC

    Strong interaction level shifts and widths in $\Sigma^-$ atoms are analyzed by using a $\Sigma$ nucleus optical potential constructed within the relativistic mean field approach. The analysis leads to potentials with a repulsive real part in the nuclear interior. The data are sufficient to establish the size of the isovector meson--hyperon coupling. Implications to $\Sigma$ hypernuclei are discussed. Comment: 18 pages, RevTex, 4 uuencoded figures, subm. Nucl.Phys.A

  • Open Access
    Authors: 
    Graham J. Schapel; Sheila J. Wallace; Gillian S. Gordon;
    Publisher: Elsevier BV

    A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994, identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales. Of 79 patient treatments with LTG and 86 with GVG, 42 patients were treated with add-on LTG, 52 with add-on GVG and 20 with both drugs simultaneously. A Kaplan-Meier curve, applied to each of the two index drugs, indicated that 71 and 62% of patients would be expected to continue taking LTG or GVG, respectively after 40 months. Improved seizure control (≥ 50%) at the time of audit was seen in 65% of LTG and 58% of GVG patient treatments for all epilepsy syndromes, but there was a higher proportion of patients with generalized epilepsy improved by LTG (28/41, 68%) than that improved by GVG (8/20, 40%), and only those with generalized epilepsy treated with LTG became seizure free (8/38, 21%). Similar proportions of patients discontinued LTG (16%) and GVG (15%) due to an adverse experience, but a higher proportion discontinued GVG (18%) compared with LTG (6%) because of lack of efficacy. This study supports the relative clinical effectiveness of LTG and GVG in the real world, where children with severe epilepsy are treated in clinical practice and serves to generate hypotheses to enable design of prospectively controlled trials, which should enable more rational use of these two drugs in the paediatric population with epilepsy.